Elevance Health, Inc.
Close on Oct 19, 2026
- Market cap
- $93.75B
- P/E (TTM)
- 19.1
- Dividend yield
- –
Earnings
Next report expected Oct 20, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 15, 2026 | Before market open | $49.80B | $6.71 | $7.45 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 22, 2026 | Before market open | $49.50B | $8.00 | $12.58 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 28, 2026 | Before market open | $49.30B | $2.47 | $3.33 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 21, 2025 | Before market open | $50.10B | $5.32 | $6.03 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 17, 2025 | Before market open | $49.40B | $7.72 | $8.84 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 17, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 23, 2025 | Before market open | $45.00B | $1.81 | $3.84 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 17, 2024 | Before market open | $44.70B | $4.36 | $8.37 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 17, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 18, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 24, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 15, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted diluted EPSnon-GAAP | FY 2026 | $27.00 | Raised |
| diluted EPSGAAP | FY 2026 | $20.10 | Raised |
| operating cash flow | FY 2026 | $6.00B | Raised |
| adjusted EPS growthnon-GAAP | 2027 | 12% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Elevance Health filed with the SEC
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
E A R N I N G S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS THIRD QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
Elevance Health Announces John Gallina to Retire as CFO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
P R E S S R E L E A S E
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS FIRST QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS FOURTH QUARTER
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS THIRD QUARTER 2022 RESULTS,
Results of operations · EX-99.1 to Form 8-K
ELEVANCE HEALTH REPORTS SECOND QUARTER 2022 RESULTS,
Results of operations · EX-99.1 to Form 8-K
ANTHEM REPORTS FIRST QUARTER 2022 RESULTS,
Results of operations · EX-99.1 to Form 8-K/A
ANTHEM REPORTS FOURTH QUARTER AND FULL YEAR 2021 RESULTS
Results of operations · EX-99.1 to Form 8-K
ANTHEM REPORTS THIRD QUARTER 2021 RESULTS,
Results of operations · EX-99.1 to Form 8-K